GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DNA Chip Research Inc (TSE:2397) » Definitions » Debt-to-EBITDA

DNA Chip Research (TSE:2397) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is DNA Chip Research Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

DNA Chip Research's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.0 Mil. DNA Chip Research's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.0 Mil. DNA Chip Research's annualized EBITDA for the quarter that ended in Dec. 2023 was 円-301.4 Mil. DNA Chip Research's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for DNA Chip Research's Debt-to-EBITDA or its related term are showing as below:

TSE:2397's Debt-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.76
* Ranked among companies with meaningful Debt-to-EBITDA only.

DNA Chip Research Debt-to-EBITDA Historical Data

The historical data trend for DNA Chip Research's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DNA Chip Research Debt-to-EBITDA Chart

DNA Chip Research Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DNA Chip Research Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DNA Chip Research's Debt-to-EBITDA

For the Diagnostics & Research subindustry, DNA Chip Research's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DNA Chip Research's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, DNA Chip Research's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DNA Chip Research's Debt-to-EBITDA falls into.



DNA Chip Research Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

DNA Chip Research's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -345.071
=0.00

DNA Chip Research's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -301.444
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


DNA Chip Research  (TSE:2397) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


DNA Chip Research Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DNA Chip Research's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


DNA Chip Research (TSE:2397) Business Description

Traded in Other Exchanges
N/A
Address
1-1-43 Suehirocho, Tsurumi-ku, Yokohama, JPN
DNA Chip Research Inc is specializing in the development of DNA microarrays. Its major business is focused on research and development, contract research service, and diagnostic support service. The company provides a wide variety of analytical services, from DNA chips to state-of-the-art next-generation sequencing. In addition, it provides consultation on experimental planning, sample preparation, statistical analysis, and manuscript preparation, catering to researchers' needs and requirements.

DNA Chip Research (TSE:2397) Headlines

No Headlines